---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-054454"
form_type: "8-K"
ticker: "STAA"
cik: "0000718937"
company_name: "STAAR SURGICAL CO"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T21:15:58.039608+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# STAAR Surgical Q1 net sales up 5% to $77.4M; net loss $0.07ps; raises FY24 EBITDA outlook

## Summary
- Net sales $77.4M (+5% YoY; +7% constant currency); ICL sales +9% on +2% units.
- Net loss $3.3M ($0.07 loss per share) vs net income $2.7M ($0.05) a year ago; Adjusted EBITDA $5.3M ($0.11) vs $10.0M ($0.20).
- U.S. sales $5M, up 15% YoY and 21% sequentially; record cash $252.1M.
- FY2024 net sales outlook reiterated at $335-$340M; Adjusted EBITDA guidance raised to ~$39M ($0.75 per share) from ~$36M.
- APAC sales +9% (China +10%); EMEA +11%; largest-ever U.S. practice commitment to EVO ICL announced.

## SEC filing metadata
- accession: 0000950170-24-054454
- form_type: 8-K
- ticker: STAA
- cik: 0000718937
- company_name: STAAR SURGICAL CO
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/718937/000095017024054454/0000950170-24-054454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/718937/000095017024054454/staa-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-054454
- JSON: https://secwatch.observer/filing/0000950170-24-054454.json
- Plain text: https://secwatch.observer/filing/0000950170-24-054454.txt

## Key facts
- Earnings Releases
  STAAR SURGICAL CO reported first quarter ended March 29, 2024 results: revenue $77.4 million, net income Net loss of $3.3 million or $0.07 loss per share, EPS $0.07 loss per share. Guidance reaffirmed.
  - Period: first quarter ended March 29, 2024
  - Revenue: $77.4 million
  - Net income: Net loss of $3.3 million or $0.07 loss per share
  - EPS: $0.07 loss per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: (EVO ICLTM) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024. First Quarter 2024 Overview • Net sales up 5% to $77.4 million and up 7% in constant currency • ICL sales up 9% and units up 2% • Gross margin at 78.9% vs. 78.3% year ago • Net loss of $3.3 million or $0.07 loss per share vs. net income of
  evidence_url: https://www.sec.gov/Archives/edgar/data/718937/000095017024054454/0000950170-24-054454-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.